Afelimomab


Also found in: Wikipedia.

Afelimomab

An anti-TNF-alpha monoconal antibody which advanced to phase 3 trials for managing sepsis and septic shock, but only offered a marginal improvement over the control arm, and has been abandoned.
Mentioned in ?
References in periodicals archive ?
Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels.
within 24 hours of controls meeting enrollment criteria Sepsis or septic 16 Post-ICU admission shock days 1, 2, or 3 Phase II/III therapeutic trials Severe sepsis 1342 Placebo 12 hours before patients with or controlled receiving drug to without septic day 28 shock (Lenercept trial) Sepsis 48 Placebo 0-168 hours after (Afelimomab trial) controlled drug infusion Sepsis 944 Placebo Baseline to ?